Drugs / Benzbromarone
Benzbromarone
also known as
Benzbromaron · Benzbromarona · Benzpromarone · Desuric · L-2214 · MJ 10061 · Narcaricin mite · NSC-85433 · +1 more
Small molecule targets SLC22A12 via inhibition
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02317861 | Dec 2014 → Jun 2015 | gout | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02790450 | Oct 2015 → Aug 2016 | idiopathic pulmonary arterial hypertension | Medical University of Graz | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05210517 | Oct 2020 → Jun 2021 | type 2 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 4 | NCT00422318 | Jan 2004 → Dec 2005 | heart failure | Tottori University Hospital | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02944214 | Oct 2016 → Dec 2019 | chronic kidney disease, impaired renal function disease | Shanghai 10th People's Hospital | Unknown | No outcome recorded |
| — | NCT02338323 | Jan 2015 → Dec 2018 | chronic kidney disease, impaired renal function disease | Shanghai 10th People's Hospital | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 2 | NCT05504083 Comparator | Sep 2022 → May 2024 | — | InventisBio Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT03185793 Comparator | Jul 2017 → Jul 2018 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT03100318 Comparator | Apr 2017 → Apr 2018 | gout | Fuji Yakuhin Co., Ltd. | Completed | Met primary |
| Phase 4 | NCT06966635 Background | Apr 2024 → Dec 2025 overdue | gout, nephrolithiasis | Huashan Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT03534037 Comparator | Feb 2020 → Dec 2021 | diastolic heart failure, metabolic syndrome X | National Defense Medical Center, Taiwan | Unknown | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Benzbromarone | “Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion...” NCT06966635 ↗10“ten people with type 2 diabetes received 1 week of empagliflozin, urate transporter 1 blocker benzbromarone, or their combination in a crossover design” PMID 35322793 ↗ Mar 2022 |
| Known as | Benzbromaron | ChEMBL registry synonym — accepted as the source's own label CHEMBL388590 ↗ |
| Known as | Benzbromarona | ChEMBL registry synonym — accepted as the source's own label CHEMBL388590 ↗ |
| Known as | Benzpromarone | ChEMBL registry synonym — accepted as the source's own label CHEMBL388590 ↗ |
| Known as | Desuric | ChEMBL registry synonym — accepted as the source's own label CHEMBL388590 ↗ |
| Known as | L-2214 | ChEMBL registry synonym — accepted as the source's own label CHEMBL388590 ↗ |
| Known as | MJ 10061 | ChEMBL registry synonym — accepted as the source's own label CHEMBL388590 ↗ |
| Known as | Narcaricin mite | ChEMBL registry synonym — accepted as the source's own label CHEMBL388590 ↗ |
| Known as | NSC-85433 | ChEMBL registry synonym — accepted as the source's own label CHEMBL388590 ↗ |
| Known as | Uroleap | ChEMBL registry synonym — accepted as the source's own label CHEMBL388590 ↗ |
| Action | Inhibit | “non-competitive inhibitor of xanthine oxidase” NCT02338323 ↗1“Solute carrier family 22 member 12 inhibitor” CHEMBL388590 ↗ |
| Modality | Small molecule | — CHEMBL388590 ↗ |
| Route | Oral | “take orally, 50mg per day, for 1 year” NCT02338323 ↗ |
| Target | SLC22A12 | “Solute carrier family 22 member 12 inhibitor” CHEMBL388590 ↗ |